Benoît J Van den Eynde, Ludwig Institute for Cancer Research, and Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium
Ken C Pang, Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Australia
Weisan Chen, Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Australia
Published online: April 2007
DOI: 10.1002/9780470015902.a0001431.pub2
Cancer cells bear markers (antigens) that identify them to the immune system, thereby making them targets for destruction by cytolytic T lymphocytes. Therapeutic cancer vaccines designed to exploit our recently gained knowledge of the identity and structure of these antigens are now being tested in clinical trials.
Keywords: tumour antigens; cytotoxic T lymphocytes
|
Figure 1. Presentation of antigenic peptide on class I and II MHC molecules (see text for explanation)
|
| References | |
| Boon T, Cerottini JC, Van den Eynde B, Van den Bruggen P and Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annual Reviews Immunology 12: 337–365. | |
| Boon T and van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. Journal of Experimental Medicine 183: 725–729. | |
| Bronte V and Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nature Reviews Immunology 5: 641–654. | |
| Davis ID, Chen W, Jackson H et al. (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proceedings of the National Academy of Sciences of the USA 101: 10697–10702. | |
| De Plaen E, Lurquin C, Lethe B et al. (1997) Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 12: 125–142. | |
| Dudley ME, Wunderlich JR, Robbins PF et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850–854. | |
| Figdor CG, de Vries IJ, Lesterhuis WJ and Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nature Medicine 10: 475–480. | |
| Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nature Reviews Immunology 4: 46–54. | |
| Old LJ and Chen YT (1998) New paths in human cancer serology. Journal of Experimental Medicine 187: 1163–1167. | |
| Pashine A, Valiante NM and Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nature Medicine 11: S63–68. | |
| Peggs KS, Quezada SA, Korman AJ and Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion Immunology 18: 206–213. | |
| Rosenberg SA, Yang JC and Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nature Medicine 10: 909–915. | |
| Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer 5: 615–625. | |
| Spiotto MT, Rowley DA and Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nature Medicine 10: 294–298. | |
| Uyttenhove C, Pilotte L, Theate I et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine 9: 1269–1274. | |
| Van den Eynde BJ and van der Bruggen P (1997) T cell defined tumor antigens. Current Opinion Immunology 9: 684–693. | |
| other van der Bruggen P, Stroobart V, Van Pel A. and Van den Eynde B (2006) Peptide Database http://cancerimmunity.org/peptidedatabase/Tcellepitopes.htm | |
| Villa LL, Costa RL, Petta CA et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology 6: 271–278. | |
| Vonderheide RH, Domchek SM, Schultze JL et al. (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clinical Cancer Research 10: 828–839. | |
| Yu P, Rowley DA, Fu YX and Schreiber H (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Current Opinion Immunology 18: 226–231. | |
| Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nature Reviews Immunology 6: 295–307. | |
| Further Reading | |
| Boon T, Coulie PG, Van den Eynde BJ and Van der Bruggen P (2006) Human T cell responses against melanoma. Annual Reviews of Immunology 24: 175–208. | |
| Gilboa E (2004) The promise of cancer vaccines. Nature Reviews Cancer 4: 401–411. | |
| Houghton AN, Gold JS and Blachere NE (2001) Immunity against cancer: lessons learned from melanoma. Current Opinion in Immunology 13: 134–140. | |
| Rammensee HG, Weinschenk T, Gouttefangeas C and Stevanovic S (2002) Towards patient-specific tumor antigen selection for vaccination. Immunological Reviews 188: 164–176. | |
| Van der Bruggen P, Zhang Y, Chaux P et al. (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunological Reviews 188: 51–64. | |
| Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer 5: 263–274. | |
Copyright © 2000-2013 by John Wiley & Sons, Inc., or related companies. All rights reserved.
